Question 1

What is the catalog number for CD13 (Myeloid Cells, Aminopeptidase N) (FITC) discontinued. see C2264-14J?

Accepted Answer

The catalog number for CD13 (Myeloid Cells, Aminopeptidase N) (FITC) discontinued. see C2264-14J is C2264-14-FITC.

Question 2

What sizes are available for CD13 (Myeloid Cells, Aminopeptidase N) (FITC) discontinued. see C2264-14J?

Accepted Answer

CD13 (Myeloid Cells, Aminopeptidase N) (FITC) discontinued. see C2264-14J is available in the following size(s): 100 µL.

Question 3

Is CD13 (Myeloid Cells, Aminopeptidase N) (FITC) discontinued. see C2264-14J in stock?

Accepted Answer

CD13 (Myeloid Cells, Aminopeptidase N) (FITC) discontinued. see C2264-14J is currently made to order / not held in immediate stock. Contact us for lead time.

Question 4

Can I request additional validation data, such as western blot images, for this product?

Accepted Answer

Additional data may be available on request. Contact our technical support team with the catalogue number and we’ll check what supporting documentation the supplier can provide.

Question 5

What documentation should I request if this product is used for a regulated or intellectual-property-sensitive application?

Accepted Answer

If the product is subject to intellectual property protections, we’ll advise on any MTA or usage restrictions before shipping. Let us know your intended end use so we can confirm what’s required upfront.

Question 6

Is this antibody conjugated?

Accepted Answer

Conjugation status, such as unconjugated, HRP, FITC, or biotin, is specified in the product name and confirmed on the datasheet.

CD13 (Myeloid Cells, Aminopeptidase N) (FITC) discontinued. see C2264-14J

Product Specifications

Clonality

Frequently Asked Questions

Explore Other Products

Caldesmon, HMW (h-Caldesmon) (Smooth Muscle Marker) (CALD1/1424R), CF740 conjugate, 0.1mg/mL

Bcl-6 (Follicular Lymphoma Marker) (BCL6/1527), CF647 conjugate, 0.1mg/mL

Anti-CD319/SLAMF7 Antibody Picoband®

Desmin (Muscle Cell Marker) (D33), Biotin conjugate, 0.1mg/mL

OX40 / CD134/ TNFRSF4 (Immuno-Oncology Target) (OX40/3108), 0.2mg/mL

CD44v3 (Marker of Tumor Metastasis) (3G5), 0.2mg/mL